GleamWall
中文EN

YARW Yarrow Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1566044 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.1%
TTM net income YoY-35.6%
TTM EPS YoY-1,140.7%
Revenue 3-yr CAGR-12.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,949.6%
Net margin-8,097.7%
FCF margin—
EBITDA margin—

Returns

ROE-67.8%
ROA-58.7%
ROIC (approx.)-108.4%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-30
Income statement
Revenue—$97,000$86,000$69,000$202,000$84,000$121,000$198,000
R&D expense$5.28M$788,000$817,000$4.88M$6.12M$9.68M$10.25M$7.31M
SG&A expense$5.47M$2.41M$3.08M$2.73M$3.27M$3.17M$2.96M$3.29M
Operating income-$10.74M-$3.10M-$3.82M-$7.54M-$9.20M-$12.77M-$13.09M-$10.40M
Pretax income—-$2.90M-$3.58M-$5.75M-$8.60M-$12.01M-$12.16M-$9.39M
Income tax—$0$0$0$0$4,000$0$0
Net income-$9.72M-$6.51M-$2.75M-$5.75M-$8.61M-$12.02M-$12.16M-$9.41M
EBITDA-$10.75M-$3.10M-$3.81M-$7.53M-$9.19M——-$10.40M
EPS (basic)-0.43-3.51-0.08-6.73-0.20—-0.29-0.22
EPS (diluted)-0.43-3.51-0.08-6.73-0.20—-0.29-0.22
Weighted avg. shares (diluted)22.59M858,00042.77M855,00042.67M—42.59M42.59M
Banking
Net interest income$925,000———————
Balance sheet
Cash & equivalents$268.86M$22.93M$24.63M$22.05M$28.21M$19.93M$16.27M$29.61M
Short-term investments—$0$297,000$17.60M$22.06M$41.59M$53.91M$48.49M
Current assets$273.96M$23.53M$25.79M$44.34M$54.91M$64.44M$73.53M$83.78M
PP&E, net$72,000$78,000$84,000$102,000$107,000$113,000——
Total assets$274.03M$23.60M$25.87M$44.72M$56.42M$66.91M$76.20M$86.65M
Current liabilities$6.51M$1.54M$1.24M$5.84M$12.29M$14.82M$12.66M$11.75M
Long-term debt$0$0$0$0$0$0$0$0
Total debt$0$0$0$0$0$0$0$0
Total liabilities$6.51M$1.54M$1.24M$5.84M$12.29M$14.82M$12.66M$11.78M
Shareholders' equity$267.52M-$79.43M-$73.43M$38.88M$44.13M$52.09M$63.54M$74.87M
Net debt-$268.86M-$22.93M-$24.63M-$22.05M-$28.21M-$19.93M-$16.27M-$29.61M
Shares outstanding11.47M668,32733.35M19.77M15.96M14.83M14.75M14.54M
Cash flow statement
Operating cash flow-$89.96M-$1.99M-$4.08M-$10.80M-$11.46M-$9.00M-$8.51M-$8.48M
Investing cash flow—$300,000$4.70M$4.67M$19.83M$12.74M-$4.82M$19.02M
Financing cash flow$265.03M-$14,000-$15,000-$34,000-$87,000-$132,000-$2,000-$3,000
Depreciation & amortization-$8,000$6,000$6,000$12,000$6,000——$0
Stock-based compensation$705,000$436,000$474,000$529,000$763,000$699,000$734,000$885,000

Free plan shows the latest 8 periods; Pro shows all 41 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.